KD6001

KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer[1].

2983061-18-1

12352203

CTLA-4

Immunology/Inflammation

Cancer-programmed cell death

Cancer

[1]Janss T, et al. EOS-215, a first-in-class TREM2 antagonist, designed to reprogram the tumor microenvironment and overcome resistance[J]. Cancer Research, 2025, 85 (8_Supplement_1) : 3136-3136.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991566/

Inhibitory Antibodies

No Development Reported